Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

Elisabeth Livingstone, Helen Gogas, Lidija Kandolf Sekulović, Friedegund Meier, Thomas Eigentler, Mirjana Ziemer, Patrick Terheyden, Anja Gesierich, Rudolf Herbst, Katharina C. Kähler, Dimitrios C. Ziogas, Željko Mijušković, Marlene Garzarolli, Claus Garbe, Alexander Roesch, Selma Ugurel, Ralf Gutzmer, Jean‐Jacques Grob, Felix Kiecker, Jochen Utikal, Christine Windemuth-Kieselbach, Sabine Eckhardt, Lisa Zimmer, Dirk Schadendorf